Clinical Trials

920 enrolled

Phase 1 Active not recruiting

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT06544655 2026-04-17

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

213 enrolled

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT07040059 2026-04-17

A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 1/2 Terminated

2 enrolled

HER 2 Positive Gastric Cancer

NCT04661150 2026-04-16

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

42 enrolled 9 charts

Stomach Neoplasms

NCT07490262 2026-04-16

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

Phase 2/3 Recruiting

680 enrolled

Carcinoma, Hepatocellular

NCT06324357 2026-04-15

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 3 Not yet recruiting

768 enrolled

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT06622057 2026-04-14

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

195 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT06469944 2026-04-13

MK-3475-06C

160 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT07431281 2026-04-13

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

2,130 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06764875 2026-04-09

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

840 enrolled

HER2-positive Gastric Cancer

NCT05568095 2026-04-02

STAR-221

1,040 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04894643 2026-03-20

PARC

Phase NA Recruiting

10 enrolled

Pancreatic Neoplasms

NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

GastrointestinalGynecologic

454 enrolled

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05464030 2026-03-18

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

Phase 1 Recruiting

200 enrolled

Colorectal Neoplasms

NCT05702229 2026-03-18

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

163 enrolled

Stomach Neoplasms

NCT06256328 2026-03-13

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

226 enrolled

Stomach Neoplasms

NCT07024615 2026-03-13

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Phase 1 Recruiting

25 enrolled

Pancreatic Ductal Adenocarcinoma

NCT07069712 2026-03-10

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

100 enrolled

Stomach Neoplasms

NCT03221426 2026-03-09

KEYNOTE-585

1,007 enrolled 25 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04882241 2026-03-06

KEYNOTE-585

120 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

757 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT03675737 2026-02-27

KEYNOTE-859

1,579 enrolled 31 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT06532006 2026-02-27

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

550 enrolled

Phase 3 Not yet recruiting

Stomach Neoplasms

NCT07412613 2026-02-27

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

386 enrolled

GastrointestinalOther solid neoplasm

Resectable Colon Cancer

NCT07432295 2026-02-25

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

180 enrolled

Adenocarcinoma Of Esophagus, Neoplasm Metastasis, Stomach Neoplasms

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

40 enrolled 67 charts

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04379596 2026-02-23

DG-03

450 enrolled

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05671822 2026-02-12

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

258 enrolled

Phase 2/3 Not yet recruiting

HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

NCT07392866 2026-02-09

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

120 enrolled

Phase 1 Active not recruiting

Carcinoma, Hepatocellular

NCT05867121 2026-02-02

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

102 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT04854668 2026-01-30

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

748 enrolled

Colorectal Neoplasms

NCT04550260 2026-01-29

KUNLUN

640 enrolled

Esophageal Squamous Cell Carcinoma

NCT05009069 2026-01-22

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

58 enrolled

Rectal Neoplasms

NCT07315750 2026-01-21

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

555 enrolled

Stomach Neoplasms

NCT07056777 2026-01-13

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

186 enrolled

Phase 2/3 Not yet recruiting

Gastrointestinal Neoplasms

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

490 enrolled

Phase 3 Not yet recruiting

HER2-positive Gastric Cancer

NCT07328919 2026-01-09

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

138 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT03869892 2025-12-22

SOLSTICE

856 enrolled

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT06686576 2025-12-18

A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

363 enrolled

Colonic Neoplasms

NCT02955940 2025-12-17

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

BreastGastrointestinalThoracic

10 enrolled

Breast Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03615326 2025-12-11

MK-3475-811

738 enrolled 22 charts 7 FDA

Phase 2/3 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT07251062 2025-11-26

A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.

737 enrolled

Phase 1 Active not recruiting

Esophageal Squamous Cell Carcinoma

NCT06328738 2025-11-19

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

275 enrolled

Phase 2 Not yet recruiting

Colorectal Neoplasms

NCT07233850 2025-11-18

A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers

300 enrolled

Esophageal Neoplasms, Colorectal Neoplasms

NCT05482893 2025-11-04

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

258 enrolled

Biliary Tract Neoplasms

NCT05382442 2025-10-14

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

254 enrolled

Colorectal Neoplasms

NCT04363801 2025-10-09

DisTinGuish

Phase 2 Terminated

247 enrolled 38 charts

Phase 1/2 Active not recruiting

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT05609370 2025-10-02

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

113 enrolled

Phase 2/3 Active not recruiting

Colorectal Neoplasms

NCT05980481 2025-09-29

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

201 enrolled